Meta tags:
description=Supporting: 2, Mentioning: 515 - Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free periods and recurrence episodes. Different targeted treatment approaches and biological drugs, currently under development, bring the promise of turning ovarian cancer into a manageable chronic disease. In this review, we discuss the current standard in the therapy for ovarian cancer, major recent studies on the new variants of conventional therapies, and new therapeutic approaches, recently approved and/or in clinical trials. The latter include anti-angiogenic therapies, polyADP-ribose polymerase (PARP) inhibitors, inhibitors of growth factor signaling, or folate receptor inhibitors, as well as several immunotherapeutic approaches. We also discuss cost-effectiveness of some novel therapies and the issue of better selection of patients for personalized treatment.;

Headings (most frequently used words):

ovarian, cancer, in, of, and, the, treatment, combined, disulfiram, with, parp, inhibitors, suppresses, fibronectin, periostin, as, prognostic, markers, slfn11, enhances, parpi, sensitivity, via, ubiquitin, mediated, stabilization, is, high, recurrence, disease, publications, advances, therapy, abstract, epithelial, typically, diagnosed, at, an, advanced, stage, current, state, art, surgery, chemotherapy, result, incidence, complete, remissions, however, rate, also, for, most, patients, eventually, becomes, continuum, symptom, free, periods, episodes, different, targeted, approaches, biological, drugs, currently, under, development, bring, promise, turning, into, manageable, chronic, this, review, show, more, cited, by, 674, references, 122,

Text of the page (most frequently used words):
the (57), and (39), with (30), cite (15), #cancer (15), via (14), #ovarian (14), this (13), that (13), citations (13), are (13), disulfiram (12), smart (11), add (11), collection (11), get (11), access (11), publisher (11), olaparib (11), paper (11), show (11), abstract (11), was (11), confidence (10), section (10), cell (10), how (10), cites (10), one (10), you (10), viewing (10), complete (10), slfn11 (9), replication (9), supporting (9), for (8), 2018 (8), results (8), values (8), niraparib (8), relatively (8), low (8), cortez (7), zhang (7), compared (7), 2026 (6), stress (6), enhancing (6), parpi (6), survival (6), eoc (6), apoptosis (6), cells (6), sensitivity (6), murai (6), prognostic (6), free (6), resection (6), cytoreduction (6), all (5), literature (5), mentioning (5), features (5), disease (5), treatment (5), scite (4), studies (4), discussion (4), under (4), drugs (4), patients (4), 2017 (4), surgery (4), self (4), kujawa (4), first (4), determined (4), combination (4), resepectively (4), higher (4), which (4), table (4), consistent (4), interestingly (4), showed (4), four (4), lines (4), front (4), oncol (4), 2023 (4), tang (4), combined (4), parp (4), inhibitors (4), suppresses (4), data (3), pricing (3), recent (3), highlight (3), recruited (3), forks (3), such (3), effectively (3), halting (3), cytotoxicity (3), inducing (3), known (3), its (3), significant (3), benefits (3), various (3), tumors (3), including (3), functions (3), inhibiting (3), repair (3), single (3), strand (3), breaks (3), potentially (3), tumor (3), our (3), findings (3), reveal (3), augments (3), rucaparib (3), concurrent (3), increase (3), levels (3), 2019 (3), dna (3), biology (3), liu (3), enhances (3), ubiquitin (3), mediated (3), stabilization (3), significance (3), clinico (3), pathological (3), median (3), dfs (3), months (3), respectively (3), these (3), observations (3), concordant (3), large (3), multivariate (3), analyses (3), indicate (3), improved (3), progression (3), overall (3), group (3), groups (3), called (3), optimal (3), between (3), suboptimal (3), 0001 (3), since (3), european (3), society (3), gynecological (3), oncology (3), esgo (3), guidelines (3), recommend (3), aim (3), frontline (3), should (3), achieve (3), macroscopic (3), residuals (3), 2020 (3), zembala (3), nożyńska (3), fibronectin (3), periostin (3), markers (3), publication (3), citation (3), part (2), research (2), solutions (2), researchers (2), terms (2), service (2), privacy (2), policy (2), statement (2), contact (2), help (2), search (2), order (2), relevance (2), unclassified (2), contrasting (2), 515 (2), report (2), other (2), select (2), types (2), summarize (2), high (2), recurrence (2), advances (2), therapy (2), start (2), trial (2), log (2), integrations (2), family, made, copyright, llc, rights, reserved, status, site, protected, recaptcha, google, apply, accessibility, legal, careers, news, press, coverage, company, blog, request, demo, faq, resources, collections, reference, check, assistant, product, henderson, 89052, usa, 10624, eastern, ave, ste, 614, customersupport, researchsolutions, com, info, powered, platform, helps, discover, evaluate, scientific, through, showing, whether, support, contradict, claim, now, has, indexed, partners, publishers, serves, users, worldwide, settings, references, 122, 532, cited, 674, export, journals, authors, 670, independent, relationship, book, preprint, 523, article, range, year, published, 232, introduction, 416, sections, statements, understand, more, epithelial, typically, diagnosed, advanced, stage, current, state, art, chemotherapy, result, incidence, remissions, however, rate, also, most, eventually, becomes, continuum, symptom, periods, episodes, different, targeted, approaches, biological, currently, development, bring, promise, turning, into, manageable, chronic, review, katarzyna, aleksandra, patrycja, tudrej, alexander, jorge, sign, set, email, alerts, doi, 1007, s00280, 017, 3501, chemother, pharmacol, skip, main, content,

Text of the page (random words):
advances in ovarian cancer therapy skip to main content features integrations data pricing log in start free trial features integrations data pricing log in start free trial cancer chemother pharmacol 2017 doi 10 1007 s00280 017 3501 8 get access via publisher summarize cite sign up to set email alerts advances in ovarian cancer therapy alexander jorge cortez 1 patrycja tudrej 2 katarzyna aleksandra kujawa 3 et al abstract epithelial ovarian cancer is typically diagnosed at an advanced stage current state of the art surgery and chemotherapy result in the high incidence of complete remissions however the recurrence rate is also high for most patients the disease eventually becomes a continuum of symptom free periods and recurrence episodes different targeted treatment approaches and biological drugs currently under development bring the promise of turning ovarian cancer into a manageable chronic disease in this review w show more summarize citations help me understand this report search citation statements order by relevance paper sections select other 416 introduction 232 discussion 54 results 8 citation types supporting 2 mentioning 515 contrasting 0 unclassified 15 year published range 2018 2018 2026 2026 publication types select article 523 other 95 preprint 31 book 25 relationship self cite 4 independent 670 authors journals ok export report add to collection cited by 674 publication s 532 citation statement s references 122 publication s supporting 2 mentioning 515 contrasting 0 unclassified 15 order by relevance settings combined treatment of disulfiram with parp inhibitors suppresses ovarian cancer tang 1 wu 2 zhang 3 et al 2023 front oncol abstract show 12 0 7 0 smart citations how this paper cites the one you are viewing we first determined the ic 50 values of olaparib and niraparib and in combination with disulfiram resepectively the ic 50 of olaparib was higher compared to the ic 50 of niraparib which was relatively low table s1 consistent with the literature 20 interestingly disulfiram showed relatively low ic 50 values with in all four cell lines section results supporting confidence 89 get access via publisher add to collection cite combined treatment of disulfiram with parp inhibitors suppresses ovarian cancer tang 1 wu 2 zhang 3 et al 2023 front oncol abstract show 12 0 7 0 smart citations how this paper cites the one you are viewing we first determined the ic 50 values of olaparib and niraparib and in combination with disulfiram resepectively the ic 50 of olaparib was higher compared to the ic 50 of niraparib which was relatively low table s1 consistent with the literature 20 interestingly disulfiram showed relatively low ic 50 values with in all four cell lines section results supporting confidence 89 get access via publisher add to collection cite fibronectin and periostin as prognostic markers in ovarian cancer kujawa 1 zembala nożyńska 2 cortez 3 et al 2020 cells self cite abstract show 54 6 38 0 smart citations how this paper cites the one you are viewing median dfs was 15 16 and 6 35 months respectively these observations are concordant with the results of large multivariate analyses that indicate improved progression free and overall survival for group of patients with complete resection compared to groups with the so called optimal between 0 1 and 1 cm and suboptimal cytoreduction p 0 0001 30 since 2017 european society of gynecological oncology esgo guidelines recommend that the aim of the frontline surgery should be to achieve the complete resection of macroscopic residuals of the disease complete cytoreduction 31 section prognostic significance of clinico pathological features supporting confidence 87 get access via publisher add to collection cite slfn11 enhances parpi sensitivity in ovarian cancer via ubiquitin mediated stabilization liu 1 li 2 zhang 3 et al 2026 dna and cell biology abstract show 0 0 0 0 smart citations how this paper cites the one you are viewing recent studies highlight that slfn11 is recruited to replication forks under such stress effectively halting replication and enhancing the cytotoxicity of replication stress inducing drugs murai et al 2018 murai et al 2019 parpi known for its significant survival benefits in various tumors including eoc functions by inhibiting the repair of single strand breaks potentially enhancing apoptosis in tumor cells cortez et al 2018 our findings reveal that oe slfn11 augments eoc cell sensitivity to rucaparib and olaparib with a concurrent increase in apoptosis levels section discussion mentioning confidence 60 get access via publisher add to collection cite combined treatment of disulfiram with parp inhibitors suppresses ovarian cancer tang 1 wu 2 zhang 3 et al 2023 front oncol abstract show 12 0 7 0 smart citations how this paper cites the one you are viewing we first determined the ic 50 values of olaparib and niraparib and in combination with disulfiram resepectively the ic 50 of olaparib was higher compared to the ic 50 of niraparib which was relatively low table s1 consistent with the literature 20 interestingly disulfiram showed relatively low ic 50 values with in all four cell lines section results supporting confidence 89 get access via publisher add to collection cite fibronectin and periostin as prognostic markers in ovarian cancer kujawa 1 zembala nożyńska 2 cortez 3 et al 2020 cells self cite abstract show 54 6 38 0 smart citations how this paper cites the one you are viewing median dfs was 15 16 and 6 35 months respectively these observations are concordant with the results of large multivariate analyses that indicate improved progression free and overall survival for group of patients with complete resection compared to groups with the so called optimal between 0 1 and 1 cm and suboptimal cytoreduction p 0 0001 30 since 2017 european society of gynecological oncology esgo guidelines recommend that the aim of the frontline surgery should be to achieve the complete resection of macroscopic residuals of the disease complete cytoreduction 31 section prognostic significance of clinico pathological features supporting confidence 87 get access via publisher add to collection cite slfn11 enhances parpi sensitivity in ovarian cancer via ubiquitin mediated stabilization liu 1 li 2 zhang 3 et al 2026 dna and cell biology abstract show 0 0 0 0 smart citations how this paper cites the one you are viewing recent studies highlight that slfn11 is recruited to replication forks under such stress effectively halting replication and enhancing the cytotoxicity of replication stress inducing drugs murai et al 2018 murai et al 2019 parpi known for its significant survival benefits in various tumors including eoc functions by inhibiting the repair of single strand breaks potentially enhancing apoptosis in tumor cells cortez et al 2018 our findings reveal that oe slfn11 augments eoc cell sensitivity to rucaparib and olaparib with a concurrent increase in apoptosis levels section discussion mentioning confidence 60 get access via publisher add to collection cite combined treatment of disulfiram with parp inhibitors suppresses ovarian cancer tang 1 wu 2 zhang 3 et al 2023 front oncol abstract show 12 0 7 0 smart citations how this paper cites the one you are viewing we first determined the ic 50 values of olaparib and niraparib and in combination with disulfiram resepectively the ic 50 of olaparib was higher compared to the ic 50 of niraparib which was relatively low table s1 consistent with the literature 20 interestingly disulfiram showed relatively low ic 50 values with in all four cell lines section results supporting confidence 89 get access via publisher add to collection cite fibronectin and periostin as prognostic markers in ovarian cancer kujawa 1 zembala nożyńska 2 cortez 3 et al 2020 cells self cite abstract show 54 6 38 0 smart citations how this paper cites the one you are viewing median dfs was 15 16 and 6 35 months respectively these observations are concordant with the results of large multivariate analyses that indicate improved progression free and overall survival for group of patients with complete resection compared to groups with the so called optimal between 0 1 and 1 cm and suboptimal cytoreduction p 0 0001 30 since 2017 european society of gynecological oncology esgo guidelines recommend that the aim of the frontline surgery should be to achieve the complete resection of macroscopic residuals of the disease complete cytoreduction 31 section prognostic significance of clinico pathological features supporting confidence 87 get access via publisher add to collection cite slfn11 enhances parpi sensitivity in ovarian cancer via ubiquitin mediated stabilization liu 1 li 2 zhang 3 et al 2026 dna and cell biology abstract show 0 0 0 0 smart citations how this paper cites the one you are viewing recent studies highlight that slfn11 is recruited to replication forks under such stress effectively halting replication and enhancing the cytotoxicity of replication stress inducing drugs murai et al 2018 murai et al 2019 parpi known for its significant survival benefits in various tumors including eoc functions by inhibiting the repair of single strand breaks potentially enhancing apoptosis in tumor cells cortez et al 2018 our findings reveal that oe slfn11 augments eoc cell sensitivity to rucaparib and olaparib with a concurrent increase in apoptosis levels section discussion mentioning confidence 60 get access via publisher add to collection cite scite is an ai powered platform that helps researchers discover and evaluate scientific literature through smart citations showing whether studies support or contradict a claim now part of research solutions scite has indexed 1 6b citations partners with 30 publishers and serves 2m users worldwide contact info customersupport researchsolutions com 10624 s eastern ave ste a 614 henderson nv 89052 usa product scite assistant search reference check collections resources pricing help faq request a demo blog company data coverage news press careers contact legal privacy policy terms of service accessibility statement this site is protected by recaptcha and the google privacy policy and terms of service apply status copyright 2026 scite llc all rights reserved made with for researchers part of the research solutions family